Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)

Exclusion Criteria

• •Received any measles, mumps, rubella, or varicella vaccine at any time prior to the study, or is anticipated to receive any of these vaccines outside the study
• •Any congenital or acquired immune deficiency, neoplastic disease, or depressed immunity
• •Received systemic immunomodulatory steroids within 3 months prior to entering the study or is expected to receive them during the course of the study
• •History of allergy or anaphylactic reaction to neomycin, gelatin, sorbitol, egg proteins, chicken proteins, or any component of VARIVAX® or M-M-R II®
• •Has any blood dyscrasias, leukemia, lymphoma, or other malignant neoplasm affecting the bone marrow or lymphatic systems
• •Received salicylates within 14 days prior to study vaccination
• •Exposed to varicella, herpes zoster, measles, mumps, or rubella in the 4 weeks prior to study vaccination
• •Received immune globulin, a blood transfusion, or blood-derived products within 5 months prior to study vaccination
• •History of seizure disorder, including febrile seizure
• •Fever illness (\>=102.2 °F \[39.0 °C\] within 72 hours prior to study vaccination
• •History of thrombocytopenia
• •Born to a human immunodeficiency virus (HIV)-infected mother
• •Has a diagnosis of active untreated tuberculosis
• •Participated in any other clinical trial (other than a surveillance study) within 30 days prior to study enrollment.